Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Abstract Background Precision medicine with gene panel testing based on next-generation sequencing for patients with cancer is being used increasingly in clinical practice. HER2, which encodes the human epidermal growth factor receptor 2 (HER2), is a potentially important driver gene. However, thera...

Full description

Bibliographic Details
Main Authors: Yohei Harada, Akemi Sato, Hideaki Nakamura, Keita Kai, Sho Kitamura, Tomomi Nakamura, Yuki Kurihara, Sadakatsu Ikeda, Eisaburo Sueoka, Shinya Kimura, Naoko Sueoka-Aragane
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
HER2
Extracellular domain
EGFR
Afatinib
Patient-derived cancer model
Online Access:https://doi.org/10.1186/s12885-022-10428-3

Similar Items

Similar Items